Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Supernus Pharm (SUPN)

Supernus Pharm (SUPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Supernus Pharm 9715 Key West Avenue ROCKVILLE MD 20850 USA

www.supernus.com P: 301-838-2500

Description:

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.

Key Statistics

Overview:

Market Capitalization, $K 1,656,281
Enterprise Value, $K 1,581,231
Shares Outstanding, K 54,735
Annual Sales, $ 607,520 K
Annual Net Income, $ 1,320 K
Last Quarter Sales, $ 164,310 K
Last Quarter Net Income, $ 1,170 K
EBIT, $ 77,110 K
EBITDA, $ 162,380 K
60-Month Beta 0.99
% of Insider Shareholders 8.76%
Float, K 49,940
% Float 91.24%
Short Volume Ratio 0.31

Growth:

1-Year Return -21.63%
3-Year Return -3.74%
5-Year Return -22.42%
5-Year Revenue Growth 48.57%
5-Year Earnings Growth -99.02%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.02 on 02/27/24
Latest Earnings Date 05/14/24
Earnings Per Share ttm 0.00
EPS Growth vs. Prev Qtr 106.90%
EPS Growth vs. Prev Year -95.35%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

SUPN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 25.69
Price/Earnings to Growth N/A
Return-on-Equity % 0.14%
Return-on-Assets % 0.09%
Profit Margin % 0.22%
Debt/Equity 0.00
Price/Sales 2.70
Price/Cash Flow 18.75
Price/Book 1.76
Book Value/Share 16.87
Interest Coverage 2.14
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar